APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

Tadeusz Robak
  • Tadeusz Robak
    Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland, Italy | robaktad@csk.umed.lodz.pl

Abstract

Over the last few years, several new agents have been under evaluation in preclinical studies as well as in early clinical trials, and have shown promise in treating CLL. These treatments include new  monoclonal antibodies (mAbs), immunomodulating agents, novel purine nucleoside analogs, Bcl-2 inhibitors and other agents. The most promising are a new mAbs targeted CD20 molecule or CD23, anti-CD40 mAbs and anti-CD37 antibody. Oblimersen , flavopiridol, and lenalidomide are also being evaluated both in pre-clinical studies and in early clinical trials. However,  available therapies are only partially efficient and there is an obvious need to develop better strategies and new, more specific and active drugs

Keywords

Chronic Lymphoid Leukemia, New Drugs, nucleoside analogs, Flavopiridol, lenalidomide, rituximab, Anti-CD23

Full Text:

PDF
HTML
Submitted: 2014-06-11 12:31:03
Published: 2010-05-07 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
114

Views:
PDF
62
HTML
1721

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185